Article Details

Olesoxime Failed to Benefit SMA Type 2 and 3 Patients, Final Trial Data Show

Retrieved on: 2020-11-20 14:26:15

Tags for this article:

Click the tags to see associated articles and topics

Olesoxime Failed to Benefit SMA Type 2 and 3 Patients, Final Trial Data Show. View article details on hiswai:

Excerpt

To confirm the therapy's potential long-term benefits, <b>Roche</b> launched a five-year, open-label, extension Phase 2 study (OLEOS; NCT02628743) ...

Article found on: smanewstoday.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo